Publicaciones en las que colabora con Germán Bou Arévalo (27)

2024

  1. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 5

  2. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

    Antimicrobial agents and chemotherapy, Vol. 68, Núm. 11, pp. e0092424

  3. Corrigendum to “Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions” [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150] (International Journal of Antimicrobial Agents (2024) 63(5), (S0924857924000682), (10.1016/j.ijantimicag.2024.107150))

    International Journal of Antimicrobial Agents

  4. Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

    Eurosurveillance, Vol. 29, Núm. 15

  5. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 10, pp. 2591-2597

  6. Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 79, Núm. 11, pp. 3023-3028

2022

  1. A New Live Auxotrophic Vaccine Induces Cross-Protection against Klebsiella pneumoniae Infections in Mice

    Vaccines, Vol. 10, Núm. 6

  2. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

  3. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

  4. Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

    Microbiology Spectrum, Vol. 10, Núm. 1

  5. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 1

  6. Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum b-Lactamase-Producing Enterobacterales"

    Antimicrobial Agents and Chemotherapy

  7. Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2